Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Journal of Genetic Counseling|June 28, 2018
Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish IndividualsSarah M Nielsen, Lenika M De Simone, Olufunmilayo I Olopade
The Neurologist|August 27, 2016
Neurological Management of Von Hippel-Lindau DiseaseTrent S Hodgson, Sarah M Nielsen, Maciej S Lesniak, et al.
Nuclear Medicine and Molecular Imaging|October 31, 2022
68Ga-DOTATATE Avid Metastatic Vertebral Renal Cell Carcinoma in the Setting of von Hippel-Lindau SyndromeMayank Patel, Abhishek Jha, Tatjana Antic, et al.
Gynecologic Oncology|June 12, 2022
Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancerBrandie Heald, Sara Mokhtary, Sarah M Nielsen, et al.
Breast Cancer Research and Treatment|September 12, 2022
Cancer risks associated with heterozygous ATM loss of function and missense pathogenic variants based on multigene panel analysisYael Laitman, Sarah M Nielsen, Rinat Bernstein-Molho, et al.
Familial Cancer|October 8, 2021
Re-evaluating cancer risks associated with the CHEK2 p.Ser428Phe Ashkenazi Jewish founder pathogenic variantYael Laitman, Sarah M Nielsen, Kathryn E Hatchell, et al.
JCO Precision Oncology|July 11, 2024
Disparate Rates of Germline Variants in Cancer Predisposition Genes in African American/Black Compared With Non-Hispanic White Individuals Between 2015 and 2022Rachel B Wyatt Castillo, Sarah M Nielsen, Elaine Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2016
Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia SyndromeSarah M Nielsen, Lindsay Rhodes, Ignacio Blanco, et al.
JCO Precision Oncology|November 12, 2022
Multigene Panel Testing Yields High Rates of Clinically Actionable Variants Among Patients With Colorectal CancerSarah E Coughlin, Brandie Heald, Dana Farengo Clark, et al.
Familial Cancer|June 30, 2011
Long-term outcomes, branch-specific expressivity, and disease-related mortality in von Hippel-Lindau type 2ASarah M Nielsen, Wendy S Rubinstein, Darcy L Thull, et al.
Pageof 6